Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (NCT06625320)
RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (60 Sites)
Showing the first 25 of 60 sites.
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Mayo Clinic Cancer Center - Phoenix — Phoenix, Arizona
- City of Hope-Duarte — Duarte, California
- Cedars-Sinai Medical Center — Los Angeles, California
- UCLA — Los Angeles, California
- UC San Diego Health Moores Cancer Center — San Diego, California
- Mission Hall UCSF — San Francisco, California
- Rocky Mountain Cancer — Aurora, Colorado
- Mayo Clinic Cancer Center - Florida — Jacksonville, Florida
- University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
- Cancer Care Centers of Brevard Inc — Palm Bay, Florida
- Moffitt Cancer Center — Tampa, Florida
- The Queen's Medical Center — Honolulu, Hawaii
- The University of Chicago Medical Center — Chicago, Illinois
- Johns Hopkins — Baltimore, Maryland
- Dana Farber Cancer Institute — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Karmanos Cancer Institute — Detroit, Michigan
- Mayo Clinic Cancer Center - Rochester — Rochester, Minnesota
- Washington University — St Louis, Missouri
- Roswell Park Cancer Institute — Buffalo, New York
- NYU Lagone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Columbia University Medical Center — New York, New York
- Duke University Medical Center — Durham, North Carolina
📞 Contact the Study Coordinator
Phone: (877) 632-6789
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pancreatic Cancer
- A Study of the Life Changes Experienced by Patients With Pancreatic Cancer — New York, New York
- Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer — Baltimore, Maryland
- Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma — Hartford, Connecticut
- Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer — Philadelphia, Pennsylvania
- Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer — Basking Ridge, New Jersey
- Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas — Baltimore, Maryland
Explore by condition: All Pancreatic Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.